Paradox of vaccination in cervical cancer and screeningBMJ 2008; 337 doi: https://doi.org/10.1136/bmj.a1049 (Published 28 July 2008) Cite this as: BMJ 2008;337:a1049
- Christian A Gericke, professor of public health policy1
- 1University of Adelaide, Adelaide, SA 5005, Australia
The development of human papillomavirus (HPV) vaccines and their potential for reducing cervical cancer incidence and mortality is generally considered an important step to improve population health worldwide. For countries without well performing cervical cancer screening programmes and lack of treatment options the current epidemiological and economic models seem applicable.
However, the assumptions underlying published …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial